Table 2 Cytoplasmic CCNB2 staining, clinicopathological characteristics and univariate Cox Regression analysis in 80 invasive breast cancer patients
Cytoplasmic CCNB2 expression | ||||||
|---|---|---|---|---|---|---|
Characteristics | Negative | Positive | P* | HR | 95% CI | P¤ |
Age (years) | 0.79 | 1.5 | 0.8-2.9 | 0.2 | ||
27-50 | 6 (24) | 19 (76) | ||||
>50 | 13 (28) | 34 (72) | ||||
Histologic type | 0.04 | 0.8 | 0.4-1.5 | 0.5 | ||
Ductal | 17 (29) | 41 (71) | ||||
Lobular | 0 (0) | 8 (100) | ||||
Ductal + lobular | 1(100) | 0 (0) | ||||
Other | 0 (0) | 4 (100) | ||||
Tumor size (mm) | 0.88 | 1.0 | 1.0-1.0 | 1.0 | ||
pT1 (0–20) | 3 (25) | 9 (75) | ||||
pT2 (>20-50) | 14 (27) | 38 (73) | ||||
pT3 (>50) | 2 (25) | 6 (75) | ||||
BRE grade | 0.99 | 1.1 | 0.8-1.5 | 0.5 | ||
I-II | 10 (28) | 26 (72) | ||||
III | 9 (25 ) | 27 (75) | ||||
Axillary lymph node status | 0.90 | 1.0 | 0.5-2.0 | 1.0 | ||
Negative | 6 (25) | 18 (75) | ||||
Positive | 13 (27) | 35 (73) | ||||
No. of axillary lymph nodes | 0.34 | 1.0 | 0.7-1.4 | 0.8 | ||
1-3 | 4 (19) | 17 (81) | ||||
≥4 | 9 (33) | 18 (67) | ||||
ER/PR status | 0.40 | 1.1 | 0.6-2.1 | 0.8 | ||
Negative | 11 (32) | 23 (68) | ||||
Positive | 8 (21) | 30 (79) | ||||
HER2/ neu status | 0.9 | 0.7 | 0.3-1.5 | 0.4 | ||
Positive | 7 (32) | 15 (68) | ||||
Negative | 10 (27) | 27 (73) | ||||
ASPM | 0.03 | 0.9 | 0.5-20 | 0.9 | ||
Negative | 10 (45) | 12 (55) | ||||
Positive | 24 (37) | 41 (63) | ||||
KIAA0101 | 0.70 | 1.1 | 0.5-2.3 | 0.8 | ||
Negative | 16 (48) | 17 (52) | ||||
Positive | 3 (8) | 36 (92) | ||||
SLC27A2 | 0.08 | 0.6 | 0.3-1.3 | 0.2 | ||
Negative | 11 (20) | 43 (80) | ||||
Positive | 8 (44) | 10 (56) | ||||
CCNB2 | 19 (26) | 53 (74) | 0.004 | 6.1 | 2.0-20 | 0.003 |